3 results
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
This is an exploratory validation study in a small group of subjects receiving a CI to verify if ECoG measurements with AB*s novel ECoG system are useful as an intra-operative tool for soft surgical techniques to spare residual hearing. This trial…
The purpose of this scientific study is to verify whether immunotherapy (L19-IL2) after a standard treatment such as radiotherapy, fights the metastatic disease more efficiently than the current standard treatment alone.